1. Home
  2. IDYA
  3. IDYA News

Latest IDEAYA Biosciences Inc. (IDYA) News on February 22, 2025

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
IDYA

Zacks

8 days ago

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)

IDYA

MT Newswires

8 days ago

RBC Lowers Price Target on IDEAYA Biosciences to $57 From $61, Keeps Outperform, Speculative Risk

IDYA

MT Newswires

9 days ago

IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDYA

Zacks

9 days ago

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

IDYA

MT Newswires

9 days ago

IDEAYA Biosciences Q4 Loss Widens, Revenue Rises

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
IDYA

PR Newswire

10 days ago

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
IDYA

PR Newswire

10 days ago

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
IDYA

Zacks

12 days ago

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

IDYA

MT Newswires

12 days ago

IDEAYA Biosciences Appoints Joshua Bleharski as Finance Chief

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
IDYA

PR Newswire

13 days ago

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

23 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025
IDYA

Insider Monkey

23 days ago

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDYA

PR Newswire

a month ago

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
IDYA

Simply Wall St.

a month ago

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
IDYA

PR Newswire

a month ago

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

IDYA

MT Newswires

2 months ago

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
IDYA

PR Newswire

2 months ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

2 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDYA

MT Newswires

2 months ago

IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
IDYA

PR Newswire

2 months ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
IDYA

PR Newswire

2 months ago

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years
IDYA

Simply Wall St.

2 months ago

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
IDYA

PR Newswire

2 months ago

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
IDYA

PR Newswire

2 months ago

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

IDYA

MT Newswires

2 months ago

IDEAYA Biosciences Nominates IDE892 as Development Candidate

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
IDYA

PR Newswire

2 months ago

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

3 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
IDYA

PR Newswire

3 months ago

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

3 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
IDYA

Insider Monkey

3 months ago

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
IDYA

PR Newswire

3 months ago

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
IDYA

PR Newswire

3 months ago

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

IDYA

MT Newswires

3 months ago

IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
IDYA

PR Newswire

3 months ago

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
IDYA

Business Wire

3 months ago

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
IDYA

Zacks

3 months ago

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

IDYA

MT Newswires

4 months ago

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, $27 Price Target

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)
IDYA

Simply Wall St.

4 months ago

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./
IDYA

PR Newswire

4 months ago

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

IDYA

MT Newswires

4 months ago

IDEAYA Biosciences Q3 Loss Narrows

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

4 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
IDYA

Zacks

4 months ago

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline
IDYA

Zacks

4 months ago

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

IDYA

MT Newswires

4 months ago

IDEAYA Biosciences Secures FDA Approval for IDE275's Investigational New Drug Application

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
IDYA

PR Newswire

4 months ago

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDYA

MT Newswires

4 months ago

IDEAYA Biosciences Reports 'Positive' Interim Phase 1 Data for Cancer Drug; Shares Rise Pre-Bell

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
IDYA

PR Newswire

4 months ago

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDYA

MT Newswires

4 months ago

UBS Initiates IDEAYA Biosciences With Buy Rating, $50 Price Target

IDYA

MT Newswires

4 months ago

Cantor Fitzgerald Initiates IDEAYA Biosciences at Overweight

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
IDYA

PR Newswire

5 months ago

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

5 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans
IDYA

Clinical Trials Arena

5 months ago

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans

IDYA

MT Newswires

5 months ago

Wedbush Trims Price Target on IDEAYA Biosciences to $52 From $54, Keeps Outperform Rating

IDYA

MT Newswires

5 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Monday

IDYA

MT Newswires

5 months ago

Ideaya Biosciences Says Phase 2 Darovasertib Trial Showed 'Clinically Meaningful' Results

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
IDYA

PR Newswire

5 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
IDYA

PR Newswire

5 months ago

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
IDYA

PR Newswire

5 months ago

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

6 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IDYA

PR Newswire

6 months ago

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

6 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat
IDYA

Simply Wall St.

6 months ago

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)
IDYA

Simply Wall St.

6 months ago

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

IDYA

MT Newswires

6 months ago

Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $60, Maintains Outperform Rating

IDYA

MT Newswires

7 months ago

IDEAYA Biosciences Shares Gain After Company Reports Q2 Net Loss

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
IDYA

PR Newswire

7 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
IDYA

Zacks

7 months ago

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

IDYA

MT Newswires

7 months ago

IDEAYA Biosciences, Biocytogen Agree to Option, License Deal for Solid Tumors Treatment Program

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
IDYA

Business Wire

7 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
IDYA

Business Wire

7 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
IDYA

PR Newswire

7 months ago

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
IDYA

PR Newswire

7 months ago

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
IDYA

Zacks

7 months ago

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%

IDYA

MT Newswires

7 months ago

Wedbush Cuts Price Target on IDEAYA Biosciences to $54 From $56, Maintains Outperform Rating

Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts
IDYA

Simply Wall St.

7 months ago

Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts

IDYA

MT Newswires

7 months ago

JPMorgan Raises Price Target on IDEAYA Biosciences to $69 From $65, Maintains Overweight Rating

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
IDYA

PR Newswire

7 months ago

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
IDYA

Zacks

7 months ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

IDYA

MT Newswires

7 months ago

RBC Raises Price Target on IDEAYA Biosciences to $61 From $53, Keeps Outperform, Speculative Risk

IDYA

MT Newswires

7 months ago

IDEAYA Biosciences Prices $263 Million Public Offering

IDEAYA Announces Pricing of Public Offering
IDYA

PR Newswire

7 months ago

IDEAYA Announces Pricing of Public Offering

IDYA

MT Newswires

7 months ago

IDEAYA Biosciences Plans to Sell Shares, Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
IDYA

PR Newswire

7 months ago

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
IDYA

Zacks

7 months ago

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Company News for July 9, 2024
IDYA

Zacks

7 months ago

Company News for July 9, 2024

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
IDYA

Zacks

7 months ago

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment
IDYA

Clinical Trials Arena

7 months ago

IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment

Top Stock Movers Now: Intel, Corning, SolarEdge, and More
IDYA

Investopedia

7 months ago

Top Stock Movers Now: Intel, Corning, SolarEdge, and More

IDEAYA Biosciences Soars on Cancer Drug Study Results
IDYA

Investopedia

7 months ago

IDEAYA Biosciences Soars on Cancer Drug Study Results

IDYA

MT Newswires

7 months ago

Wedbush Raises Price Target on IDEAYA Biosciences to $56 From $52, Maintains Outperform Rating

Why Ideaya Biosciences Just Made Its Most Bullish Move Since March
IDYA

Investor's Business Daily

7 months ago

Why Ideaya Biosciences Just Made Its Most Bullish Move Since March

IDYA

MT Newswires

7 months ago

Ideaya Biosciences Reports Positive Results for Potential Non-Small Cell Lung Cancer Treatment -- Shares Rise Pre-Bell

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
IDYA

PR Newswire

7 months ago

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

IDYA

MT Newswires

7 months ago

Mizuho Securities Initiates IDEAYA Biosciences at Outperform With $50 Price Target

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
IDYA

PR Newswire

8 months ago

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA

PR Newswire

8 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial
IDYA

Clinical Trials Arena

8 months ago

IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
IDYA

PR Newswire

8 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
IDYA

PR Newswire

8 months ago

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors

Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years
IDYA

Simply Wall St.

8 months ago

Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years

Share on Social Networks: